Rajaa Chatila1, Joseph Mansour1, Anas Mugharbil2, Ghazi Nsouli3, Lana O'Son1, Edouard Sayad1, Mary E Deeb4. 1. Gilbert and Rose-Marie Chagoury School of Medicine, 502749Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon. 2. 36696Makassed General Hospital, Beirut, Lebanon. 3. 197781Rafik Hariri University Hospital, Beirut, Lebanon. 4. 37607Lebanese American University (LAU), Beirut, Lebanon.
Abstract
BACKGROUND: Scarce data exist about colorectal cancer (CRC) presentation and outcomes in Lebanon. The aim of this study is to describe the characteristics of Lebanese patients diagnosed with colorectal cancer, particularly the method of detection, age of onset, stage at presentation, treatment modalities, and survival. METHODS: This is a retrospective study of a cohort of patients with CRC, diagnosed between 2005 and 2010, admitted to 6 major university-affiliated medical centers in Lebanon. RESULTS: The total sample consisted of 586 patients (median age: 64 years; M:F ratio: 1.25). The most common presenting symptoms were changes in bowel habits, abdominal pain, and blood per rectum. Only 3% had been diagnosed by screening colonoscopy. Of the patients diagnosed with CRC younger than 50 years of age, 72.5% had a positive family history (P = .07). More than two-thirds of patients had an advanced stage of the disease III and IV at presentation. The Kaplan-Meier-estimated survival rate was 0%, 44.5%, 70.2%, and 78.5% for those with stage IV, III, II, and I, respectively (P = .0001), and did not vary by age nor gender of the patient. There was no differential in survival estimate for patients with stage II and III by number of chemotherapy cycles received. However, there was a significant difference in median survivorship for patients with metastatic stage IV disease; those who received less than or equal to 9 cycles had a median survivorship of 2 years (CI: 1.31-2.68) compared to 4 years (CI: 2.36-5.63) for those who received more than 9 cycles (P = .047). The cox regression showed while controlling for age and gender that patients diagnosed at stage IV had a hazard ratio of 8.81 (3.20-24.22) compared to those who were diagnosed at stage I (P = .047). CONCLUSIONS: Lebanese patients affected by colorectal cancer tend to present with advanced disease stages, leading to poor prognosis and survival.
BACKGROUND: Scarce data exist about colorectal cancer (CRC) presentation and outcomes in Lebanon. The aim of this study is to describe the characteristics of Lebanese patients diagnosed with colorectal cancer, particularly the method of detection, age of onset, stage at presentation, treatment modalities, and survival. METHODS: This is a retrospective study of a cohort of patients with CRC, diagnosed between 2005 and 2010, admitted to 6 major university-affiliated medical centers in Lebanon. RESULTS: The total sample consisted of 586 patients (median age: 64 years; M:F ratio: 1.25). The most common presenting symptoms were changes in bowel habits, abdominal pain, and blood per rectum. Only 3% had been diagnosed by screening colonoscopy. Of the patients diagnosed with CRC younger than 50 years of age, 72.5% had a positive family history (P = .07). More than two-thirds of patients had an advanced stage of the disease III and IV at presentation. The Kaplan-Meier-estimated survival rate was 0%, 44.5%, 70.2%, and 78.5% for those with stage IV, III, II, and I, respectively (P = .0001), and did not vary by age nor gender of the patient. There was no differential in survival estimate for patients with stage II and III by number of chemotherapy cycles received. However, there was a significant difference in median survivorship for patients with metastatic stage IV disease; those who received less than or equal to 9 cycles had a median survivorship of 2 years (CI: 1.31-2.68) compared to 4 years (CI: 2.36-5.63) for those who received more than 9 cycles (P = .047). The cox regression showed while controlling for age and gender that patients diagnosed at stage IV had a hazard ratio of 8.81 (3.20-24.22) compared to those who were diagnosed at stage I (P = .047). CONCLUSIONS: Lebanese patients affected by colorectal cancer tend to present with advanced disease stages, leading to poor prognosis and survival.
Authors: Harindra Jayasekara; Dallas R English; Andrew Haydon; Allison M Hodge; Brigid M Lynch; Christophe Rosty; Elizabeth J Williamson; Mark Clendenning; Melissa C Southey; Mark A Jenkins; Robin Room; John L Hopper; Roger L Milne; Daniel D Buchanan; Graham G Giles; Robert J MacInnis Journal: Int J Cancer Date: 2017-10-04 Impact factor: 7.396
Authors: Veronica Aran; Ana Paula Victorino; Luiz Claudio Thuler; Carlos Gil Ferreira Journal: Clin Colorectal Cancer Date: 2016-02-13 Impact factor: 4.481
Authors: Axel Grothey; Alberto F Sobrero; Anthony F Shields; Takayuki Yoshino; James Paul; Julien Taieb; John Souglakos; Qian Shi; Rachel Kerr; Roberto Labianca; Jeffrey A Meyerhardt; Dewi Vernerey; Takeharu Yamanaka; Ioannis Boukovinas; Jeffrey P Meyers; Lindsay A Renfro; Donna Niedzwiecki; Toshiaki Watanabe; Valter Torri; Mark Saunders; Daniel J Sargent; Thierry Andre; Timothy Iveson Journal: N Engl J Med Date: 2018-03-29 Impact factor: 91.245
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: David P Taylor; Gregory J Stoddard; Randall W Burt; Marc S Williams; Joyce A Mitchell; Peter J Haug; Lisa A Cannon-Albright Journal: Genet Med Date: 2011-05 Impact factor: 8.822
Authors: S Jane Henley; Elizabeth M Ward; Susan Scott; Jiemin Ma; Robert N Anderson; Albert U Firth; Cheryll C Thomas; Farhad Islami; Hannah K Weir; Denise Riedel Lewis; Recinda L Sherman; Manxia Wu; Vicki B Benard; Lisa C Richardson; Ahmedin Jemal; Kathleen Cronin; Betsy A Kohler Journal: Cancer Date: 2020-03-12 Impact factor: 6.921
Authors: Tony Ibrahim; Claude Saer-Ghorra; Vivane Trak-Smayra; Samah Nadiri; Charbel Yazbeck; Maria Baz; Joseph G Kattan Journal: Ann Saudi Med Date: 2018 Jul-Aug Impact factor: 1.526